Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
38.79
+0.65 (1.70%)
At close: Jul 2, 2026, 4:00 PM EDT
40.04
+1.25 (3.22%)
After-hours: Jul 2, 2026, 7:52 PM EDT
Company Description
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases.
It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren’s disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Immunovant, Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 315 |
| CEO | Eric Venker |
Contact Details
Address: 1000 Park Forty Plaza, Suite 210 Durham, North Carolina 27713 United States | |
| Phone | 917 410 3120 |
| Website | immunovant.com |
Stock Details
| Ticker Symbol | IMVT |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 1764013 |
| CUSIP Number | 45258J102 |
| ISIN Number | US45258J1025 |
| Employer ID | 83-2771572 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Eric Venker M.D., Pharm.D. | Chief Executive Officer and Director |
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board |
| Melanie Gloria B.S.N. | Chief Operating Officer |
| Christopher A. Van Tuyl Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Tiago M. Girao CPA | Chief Financial Officer |
| Dr. Jay S. Stout M.S., Ph.D. | Chief Technology Officer |
| Christine Blodgett | Senior Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 26, 2026 | 144 | Filing |
| Jun 26, 2026 | 144 | Filing |
| Jun 26, 2026 | 144 | Filing |
| Jun 26, 2026 | 144 | Filing |
| Jun 15, 2026 | 144 | Filing |
| May 28, 2026 | 144 | Filing |
| May 20, 2026 | 144 | Filing |
| May 20, 2026 | 10-K | Annual Report |
| May 20, 2026 | 8-K | Current Report |
| May 1, 2026 | 144 | Filing |